Prolactin, flupenthixol decanoate and first episode schizophrenia – clinical and laboratory correlates
- 47 Downloads
First-episode psychosis (FEP) patients are more sensitive to neuroleptic side-effects such as hyperprolactinemia. We examined the prolactin levels of previously minimally treated patients with first episode schizophrenia over their first year of treatment with flupenthixol decanoate and the relationship between prolactin levels, gender and clinical features of schizophrenia. Prolactin levels were assessed at three monthly intervals in 126 patients with first-episode schizophrenia in a single-site study conducted over 12 months during treatment with flupenthixol decanoate according to a fixed protocol. The mean prolactin level for the total sample was 11.91 ng/ml (standard deviation [SD]15.52) at baseline. Women had higher levels of prolactin than men at month 3, 6 and 12, reaching statistical significance at month 12 (p = 0.02). At 12 months more women than men had hyperprolactinemia (defined as more than 20 ng/ml for males, and as more than 25 ng/ml for females (p = 0.007). Using a mixed effect model, there was a significant association between prolactin change scores over 12 months and gender (p = 0.025) as well as Positive and Negative Syndrome Scale (PANSS) total scores (p = 0.001). In addition female gender (p = 0.04) and age (p = 0.02) correlated with the risk of hyperprolactinemia as categorical variable. In this study treatment with flupenthixol decanoate was associated with relatively low levels of hyperprolactinemia, likely owing to flupenthixol’s relatively atypical mode of action, as well as to the low doses used in our study. We found an inverse correlation between total PANSS scores and prolactin levels, which could support the suggested theory of prolactin having antipsychotic properties. Our study confirms the importance of gender on the prolactin raising effects of antipsychotic treatment.
KeywordsHyperprolactinemia Long acting injectable Antipsychotic Gender
We acknowledge Karis Moxley (Department of Psychiatry, Stellenbosch University) for editing of manuscript. We thank the Schizophrenia Research Team of Stellenbosch University, as well as Professor Peter Haddad for his input.
This study was supported by the Medical Research Council of South Africa and the New Partnership for Africa’s Development (NEPAD) initiative through the Department of Science and Technology of South Africa.
- Bargiota SI, Bonotis KS, Messinis IE, Angelopoulos NV (2013) The effects of antipsychotics on prolactin levels and women’s menstruation. Schizophr Res Treat 502697:1–10Google Scholar
- Chiliza B, Oosthuizen P, Emsley R (2008) First-episode psychosis: an update. S Afr J Psychiatry 14(1):14–19Google Scholar
- Crespo-Facorro B, Ortiz-Garcia de la Foz V, Suarez-Pinilla P, Valdizan EM, Pérez-Iglesias R, Amado-Señaris JA et al (2017) Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: analysis of a randomized open-label 1 year study. Schizophr Res 189(2017):134–141CrossRefGoogle Scholar
- da Silva TL, Ravindran AV (2015) Contribution of sex hormones to gender differences in schizophrenia: a review. Asian J Psychiatr 18:2–14Google Scholar
- First M, Spitzer RL, Gibbon ML, Williams J (2002) Structured clinical interview for DSM-IV-TR axis I disorders, research version, patient edition.Google Scholar
- ICH harmonized tripartite guideline (2001) Guideline for good clinical practice. J Postgrad Med 47(1):45–50Google Scholar
- Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, Gheorghe MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371(9618):1085–1097CrossRefGoogle Scholar
- Marrag I, Hajji K, Braham MY, Dhifallah M, Nasr M (2015) Antipsychotics and hyperprolactinemia: prevalence and risk factors. Ann Psychiatry Ment Health 3(6):1047Google Scholar
- Matei VP, Purnichi T, Mihailescu A, Grigoras R (2019) Prolactin level in patients with First episode schizophrenia treated for one year with atypical antipsychotics. Acta Endocrinol 14(4):483–490Google Scholar
- McEvoy JP, Lieberman JA, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD (2007) Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatr 164(7):1050–1060CrossRefGoogle Scholar
- Sykes DA, Moore H, Stott L, Holliday N, Javitch JA, Lane JR et al (2017) Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D2 receptors. Nat Commun 763(8):1–11Google Scholar